Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China · Delayed Price · Currency is CNY 21.90
-0.29 (-1.31%)
At close: Jun 11, 2026
Enwei Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 48.14 | 51.94 | 37.5 | 86.31 | 67.8 | 101.73 |
Depreciation & Amortization | 47.47 | 47.47 | 46.48 | 34.83 | 30.91 | 30.5 |
Other Amortization | 4.82 | 4.82 | 6.23 | 6.55 | 6.88 | 5.59 |
Loss (Gain) From Sale of Assets | 0.14 | 0.14 | 0.26 | 0.04 | - | - |
Asset Writedown & Restructuring Costs | 4.42 | 4.42 | 5.44 | 0.58 | 1.65 | 0.07 |
Loss (Gain) From Sale of Investments | -5.2 | -5.2 | -3.49 | -3.74 | -0.59 | 0.44 |
Other Operating Activities | -18.27 | 6.1 | 23.84 | 0.35 | -1.56 | -0.52 |
Change in Accounts Receivable | -21.12 | -21.12 | -36.43 | -9.67 | -69.89 | 30.16 |
Change in Inventory | 16.43 | 16.43 | -12.06 | -2.9 | 5.4 | -31.39 |
Change in Accounts Payable | 3.16 | 3.16 | 12.96 | -27.81 | 22.12 | -50.73 |
Operating Cash Flow | 81.42 | 109.59 | 78.92 | 84.01 | 62.35 | 87.58 |
Operating Cash Flow Growth | -16.52% | 38.87% | -6.06% | 34.73% | -28.80% | 11.53% |
Capital Expenditures | -56.85 | -56.38 | -50.23 | -134.05 | -23.56 | -38.21 |
Sale of Property, Plant & Equipment | 0.04 | 0.04 | 0.34 | 0.15 | - | - |
Cash Acquisitions | -0.07 | -0.07 | - | - | - | - |
Investment in Securities | -1,694 | -1,694 | -1,018 | -685.5 | -221.5 | - |
Other Investing Activities | 1,670 | 1,671 | 957.37 | 775.22 | 1.05 | 0.52 |
Investing Cash Flow | -80.55 | -78.83 | -110.62 | -44.18 | -244.01 | -37.7 |
Long-Term Debt Issued | - | - | 241.8 | - | - | - |
Long-Term Debt Repaid | - | -11.69 | -48.09 | - | - | - |
Net Debt Issued (Repaid) | -11.69 | -11.69 | 193.71 | - | - | - |
Issuance of Common Stock | 10.77 | 10.77 | 18.36 | - | 470.75 | - |
Repurchase of Common Stock | - | - | -70.01 | -33 | - | - |
Common Dividends Paid | -57 | -20.78 | -56.96 | -112.22 | - | -46 |
Other Financing Activities | 0.66 | - | - | - | -12.28 | -2.41 |
Financing Cash Flow | -57.25 | -21.69 | 85.1 | -145.22 | 458.47 | -48.41 |
Foreign Exchange Rate Adjustments | -0 | -0 | 0 | -0.03 | 0.16 | -0.24 |
Net Cash Flow | -56.38 | 9.08 | 53.41 | -105.41 | 276.98 | 1.23 |
Free Cash Flow | 24.57 | 53.21 | 28.69 | -50.04 | 38.8 | 49.36 |
Free Cash Flow Growth | -52.07% | 85.50% | - | - | -21.41% | 4.24% |
Free Cash Flow Margin | 2.79% | 5.91% | 3.53% | -6.37% | 5.61% | 7.26% |
Free Cash Flow Per Share | 0.24 | 0.52 | 0.28 | -0.49 | 0.46 | 0.63 |
Cash Income Tax Paid | 78.13 | 76.36 | 80.87 | 84.86 | 58.93 | 79.2 |
Levered Free Cash Flow | 12 | 74.46 | 26.78 | -68.83 | 41.25 | 21.46 |
Unlevered Free Cash Flow | 13.44 | 76.06 | 28.29 | -68.83 | 41.25 | 21.46 |
Change in Working Capital | -0.1 | -0.1 | -37.33 | -40.9 | -42.73 | -50.23 |